Partner Headlines - BMRN

  1. BioMarin Gets Price Target Hike On Pipeline Strength

    IBD
  2. 2 DMD drugs make progress

    IBD
  3. BioMarin, Sarepta Muscular Dystrophy Drugs Progress

    IBD
  4. Baird Downgrades BioMarin Pharmaceutical To Neutral

    Benzinga
  5. Benzinga's Volume Movers

    Benzinga
  6. Benzinga's Top Downgrades

    Benzinga
  7. Mid-Afternoon Market Update: BioMarin Pharmaceutical Jumps Following ...

    Benzinga
  8. Mid-Day Market Update: Oracle Drops On Downbeat Results; Radius ...

    Benzinga
  9. BioMarin Stock Hits High On Dwarfism Drug Success

    IBD
  10. Mid-Morning Market Update: Markets Open Higher; Kroger Earnings ...

    Benzinga
  11. Benzinga's Volume Movers

    Benzinga
  12. Morning Market Gainers

    Benzinga
  13. Dollar, Data Boost Stock Futures; Oracle Tumbles, Taser Gains

    IBD
  14. Benzinga's Top #PreMarket Gainers

    Benzinga
  15. BIOMARIN PHARMA

    IBD
  16. Pier 1, BioMarin, HomeAway & Oracle Lead Wednesday's After-Hours ...

    Benzinga
  17. BMN 111 (vosoritide) Improves Growth Velocity in Children With ...

    Benzinga
  18. BioMarin Submits Drisapersen MAA to EMA for the Treatment of ...

    Benzinga
  19. Benzinga's Top Initiations

    Benzinga
  20. Barclays Initiates BioMarin Pharmaceutical With Overweight

    Benzinga
  21. Sarepta Soars On New Hope For Muscular-Dystrophy Drug

    IBD
  22. Alexion's $8.4 Billion Synageva Buyout Spooks Street

    IBD
  23. BIOMARIN PHARMA

    IBD
  24. BioMarin Completes Rolling NDA Submission to FDA for Drisapersen ...

    Benzinga
  25. J.P. Morgan's 3 Biotechnology Picks

    GuruFocus
  26. What Evercore Is Watching At BioMarin Pharmaceutical

    Benzinga
  27. BioMarin To Report Revenue In-line With Consensus, Wedbush Says

    Benzinga
  28. Why Muscular Dystrophy Is Biotech's Favorite Orphan

    IBD
  29. Bank Of America Upgrades Sarepta Therapeutics On 'Increased Conviction' ...

    Benzinga
  30. Regeneron Q4 Sales, 2015 Outlook Upbeat On Eylea

    IBD
  31. BIOMARIN PHARMA

    IBD
  32. State Of The Union Lights Up Biotech

    Benzinga
  33. Nomura Analyst Sees Fast Growth At BioMarin Pharmaceutical

    Benzinga
  34. UPDATE: Nomura Raises Price Target On BioMarin Pharmaceutical ...

    Benzinga
  35. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  36. Regeneron Jumps On Favorable Cholesterol Drug Report

    IBD
  37. 5 Potential Blockbuster Drugs Set To Launch In 2015

    IBD
  38. What Investors Are Looking For In NPS Pharmaceuticals Ahead Of ...

    Benzinga
  39. BioMarin CEO Sees Big Future For Prosensa Drug

    IBD
  40. UPDATE: UBS Securities Reiterates On BioMarin Pharmaceutical ...

    Benzinga
  41. FDA Grants BioMarin Orphan Drug Designation for NAGLU Fusion ...

    Benzinga
  42. BioMarin Will Report Breadth of Innovative Development Pipeline ...

    Benzinga
  43. Benzinga's M&A Chatter for Monday November 24, 2014

    Benzinga
  44. BioMarin buying Prosensa

    IBD
  45. Trio Of Major Deals Disclosed

    IBD
  46. Mid-Afternoon Market Update: Trina Solar Drops After Quarterly ...

    Benzinga
  47. Mid-Day Market Update: Dow Edges Lower; Platinum Underwriters ...

    Benzinga
  48. Mid-Morning Market Update: Markets Open Higher; BioMarin To Acquire ...

    Benzinga
  49. Benzinga's Volume Movers

    Benzinga
  50. BioMarin Buying Prosensa, Backing Up Troubled Drug

    IBD
  51. Stocks Hitting 52-Week Highs

    Benzinga
  52. Morning Market Movers

    Benzinga
  53. Stock Futures Trending Higher; Kate Spade Bags An Upgrade

    IBD
  54. BioMarin Pharmaceuticals To Acquire Prosensa

    Benzinga
  55. Benzinga's Top #PreMarket Gainers

    Benzinga
  56. US Stock Futures Up Ahead Of Economic Data

    Benzinga
  57. Stocks Hitting 52-Week Highs

    Benzinga
  58. Benzinga's Top Upgrades

    Benzinga
  59. Benzinga's M&A Chatter for Tuesday October 21, 2014

    Benzinga
  60. BioMarin Weathers The Storm

    Benzinga
  61. 4 Top-Rated Drugmakers Beat Q2 Earnings Estimates

    IBD
  62. Biogen Hemophilia Drugs Launch Into The Unknown

    IBD
  63. UPDATE: Credit Suisse Upgrades BioMarin Pharmaceutical

    Benzinga
  64. Benzinga's Top Upgrades

    Benzinga
  65. BioMarin, Medivation Buck Biotech Short Interest Trend (BIIB, ...

    Benzinga
  66. Amgen, BioMarin Lead Biotech Short Interest Trend (AMGN, BIIB, ...

    Benzinga
  67. Top Trending Tickers On StockTwits For February 18

    Benzinga
  68. BioMarin Bucks Biotech Short Interest Trend (BIIB, BMRN, MDVN)

    Benzinga
  69. You Can No Longer Ignore Biotech

    GuruFocus
  70. New Year Short Interest Swings In Biotech (BIIB, BMRN, MDVN)

    Benzinga
  71. Celgene, Dendreon Lead Short Interest Trend In Biotechs (BMRN, ...

    Benzinga
  72. UPDATE: Piper Jaffray Initiates Coverage on BioMarin Pharmaceutical ...

    Benzinga
  73. UPDATE: Piper Jaffray Initiates On BioMarin Pharmaceuticals On ...

    Benzinga
  74. BioMarin Wins FDA Panel Vote, Cuts Deal With Myriad

    IBD
  75. Benzinga's Top #PreMarket Gainers

    Benzinga
  76. BioMarin Confirms FDA Panel Recommends Approval of Vimizim for ...

    Benzinga
  77. BioMarin Stock Trading Halted Today for FDA Endocrinologic and ...

    Benzinga
  78. Gilead Sciences Leads In Rising Short Interest Among Biotechs ...

    Benzinga
  79. Catalyst Stock Plunge: Ugly In Orphan Drug Land

    YCharts
  80. BioMarin Initiates Phase 3 BMN 673 Trial for Metastatic gBRCA ...

    Benzinga
  81. Short Sellers Retreat From Biogen Idec, Move On Pharmacyclics ...

    Benzinga
  82. US Oncology, Biomarin Announce Collaboration to Launch PARP Inhibitor ...

    Benzinga
  83. Roche

    IBD
  84. BioMarin Announces 5 Poster Presentations on BMN 673 at AACR-NCI-EORTC ...

    Benzinga
  85. Short Sellers Move On Amgen, Vertex (AMGN, PCYC, VRTX)

    Benzinga
  86. Orphan Drugs: No (Payer) News Is Good News

    YCharts
  87. BioMarin Presents Positive Phase 1/2 Data on BMN 673 in Breast ...

    Benzinga
  88. BioMarin, Celgene Lead Trend in Biotech Short Interest (BRMN, ...

    Benzinga
  89. Market Primer: Friday, September 20: US Markets Fall As Investors ...

    Benzinga
  90. Benzinga's M&A Chatter for Thursday September 19, 2013

    Benzinga
  91. Report: Roche Lines up $15B in Debt to Buy BioMarin

    FoxBusiness
  92. Benzinga's Volume Movers

    Benzinga
  93. Benzinga's Top Pre-Market Gainers

    Benzinga
  94. UPDATE: Stifel Downgrades BioMarin Pharmaceutical on Appropriate ...

    Benzinga
  95. Benzinga's Top Pre-Market Gainers

    Benzinga
  96. Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, ...

    Benzinga
  97. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  98. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  99. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  100. UPDATE: Stifel Nicolaus Upgrades BioMarin Pharmaceutical on Catalysts

    Benzinga
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!